|
| 37879077 | Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. | Blood | 2024 |
| 38086946 | Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. | Leukemia | 2024 |
| 38054837 | Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. | Leuk Lymphoma | 2024 |
| 37946611 | Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. | Br J Haematol | 2024 |
| 37646654 | Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. | Haematologica | 2024 |
| 36322818 | Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. | Blood Adv | 2023 |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 |
| 37526512 | Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. | Leuk Lymphoma | 2023 |
| 37665752 | Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. | Am J Hematol | 2023 |
| 37798329 | What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia. | Leukemia | 2023 |
| 37485584 | Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. | Am J Hematol | 2023 |
| 37854355 | The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. | Ther Adv Hematol | 2023 |
| 37703506 | Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. | J Clin Oncol | 2023 |
| 37699357 | Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. | Acta Haematol | 2023 |
| 37515433 | Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. | Am J Hematol | 2023 |
| 37652074 | Revisiting six established practices in the treatment of chronic myeloid leukaemia. | Lancet Haematol | 2023 |
| 37841255 | Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. | Front Immunol | 2023 |
| 37735426 | Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. | Blood Cancer J | 2023 |
| 37690903 | Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37647601 | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. | Blood Adv | 2023 |
| 37608562 | Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. | Br J Haematol | 2023 |
| 37822571 | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. | Ther Adv Hematol | 2023 |
| 37730483 | Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. | Clin Lymphoma Myeloma Leuk | 2023 |
| 38040680 | Early mortality after chemotherapy as a quality indicator-the leukemia perspective. | Blood Cancer J | 2023 |
| 37769040 | Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. | Cancer | 2023 |
| 37530627 | Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. | Blood Adv | 2023 |
| 35633516 | Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. | Am J Hematol | 2023 |
| 37088793 | Management of chronic myeloid leukemia in 2023 - common ground and common sense. | Blood Cancer J | 2023 |
| 36951293 | Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. | Br J Haematol | 2023 |
| 36951163 | Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). | Haematologica | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 36949155 | Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. | Leukemia | 2023 |
| 37187201 | Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. | Lancet Haematol | 2023 |
| 36990622 | Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. | Lancet Haematol | 2023 |
| 37386016 | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. | Blood Cancer J | 2023 |
| 37185307 | Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. | Leukemia | 2023 |
| 37183966 | Ultrasensitive NGS MRD assessment in Ph+â¿¿ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. | Am J Hematol | 2023 |
| 37345570 | CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. | Am J Hematol | 2023 |
| 36977823 | Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. | Leukemia | 2023 |
| 37243913 | The role of therapy in the outcome of patients with myelofibrosis. | Cancer | 2023 |
| 37145496 | Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. | Clin Adv Hematol Oncol | 2023 |
| 37441846 | Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. | Blood | 2023 |
| 37308342 | Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37276510 | Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. | Blood Adv | 2023 |
| 37104058 | Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. | Blood Adv | 2023 |
| 37102976 | A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. | Blood Cancer Discov | 2023 |
| 37003279 | Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. | Lancet Haematol | 2023 |
| 37334870 | Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. | Am J Hematol | 2023 |
| 37131217 | Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. | J Hematol Oncol | 2023 |
| 37066354 | Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemia. | bioRxiv | 2023 |